An alternative therapy for patients with hepatic impairment?
Choo
Su-Pin
SP
Venook
Alan P
AP
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D000068818:Cetuximab; D056486:Chemical and Drug Induced Liver Injury; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced / Q000150:complications*; D008107:Liver Diseases / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab